Point72 DIFC Ltd Acquires New Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Point72 DIFC Ltd purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 8,992 shares of the company’s stock, valued at approximately $124,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Quintet Private Bank Europe S.A. increased its position in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after buying an additional 1,000 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth approximately $113,000. Hsbc Holdings PLC acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $163,000. Bayesian Capital Management LP acquired a new stake in shares of Day One Biopharmaceuticals during the first quarter valued at $221,000. Finally, NEOS Investment Management LLC purchased a new stake in Day One Biopharmaceuticals during the 4th quarter worth about $226,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Up 0.5 %

DAWN stock opened at $14.00 on Wednesday. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $18.07. The company has a market capitalization of $1.22 billion, a P/E ratio of -5.58 and a beta of -1.51. The firm has a 50 day simple moving average of $14.08 and a 200-day simple moving average of $14.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.70. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million. On average, research analysts predict that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, July 30th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. JPMorgan Chase & Co. lowered their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Piper Sandler reiterated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Finally, Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the company from $11.00 to $24.00 in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.71.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Jeremy Bender sold 10,681 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $149,534.00. Following the sale, the chief executive officer now directly owns 98,932 shares in the company, valued at approximately $1,385,048. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. The disclosure for this sale can be found here. Insiders sold a total of 68,748 shares of company stock worth $1,009,272 over the last 90 days. Insiders own 8.40% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.